Barclays raised the firm’s price target on Natera (NTRA) to $280 from $270 and keeps an Overweight rating on the shares. The firm says “conservative” guidance sets the company up another year of beats and raises.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera: Underpenetrated Growth, Emerging Catalysts, and a Clear Path to Cash Flow Support a Buy Rating
- Natera reports FY25 EPS ($1.52), consensus ($2.42)
- Natera says Phase 2 SINERGY trial met primary endpoint
- Natera Inc. (NTRA) Q4 Earnings Cheat Sheet
- IHI, IHE, ARKG: Specialty Healthcare ETFs Can Help Boost a Portfolio